Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma

Amitkumar Mehta, MD, associate professor of medicine, associate director, Hematology and Oncology Fellowship Program, director, Phase I Program, co-director, CAR-T Program, University of Alabama at Birmingham (UAB) Bone Marrow Transplant Program, co-director, Cutaneous T Cell Lymphoma Clinic, The Kirkin Clinic, director and principal investigator, Lymphoma Tissue Bank, and director, UAB Lymphoma Working Group, UAB Medicine, discusses the complexities and considerations surrounding the sequencing of CAR T-cell therapies and bispecific antibodies in the treatment of patients with non-Hodgkin lymphoma.

The introduction of new agents into the therapeutic landscape for any oncologic or hematologic malignancy presents new challenges, particularly in determining the optimal order in which available treatments should be administered, Mehta says. Currently, the best sequence for CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory non-Hodgkin lymphoma remains unclear, Mehta explains

A collaborative approach between academic institutions and community health care providers is needed to address questions regarding the sequencing of these agents, Mehta says. Given the increasing number of therapeutic options, it is essential for clinicians to develop comprehensive treatment plans tailored to each patient's specific needs, he adds. Collaboration between sites ensures that patients receive timely access to advanced therapies, such as CAR T-cell therapy or bispecific antibodies, and maintains continuity of care with local physicians, Mehta notes

In Mehta's practice, he explains that enhanced communication between academic centers and community practitioners has proven to be effective. Regular discussions and consultations enable the coordination of complex treatment strategies, allowing for the efficient processing of CAR T-cell therapy or the initiation of a bispecific antibody . This approach ensures that patients receive the most appropriate therapy and facilitates a smooth transition back to community care, where ongoing management can continue under the guidance of local providers, he explains.

Collaborative efforts such as these are the cornerstone of effective lymphoma management as the treatment landscape continues to evolve, Mehta continues. Academic and community providers can optimize treatment sequencing and ensure that patients receive the best care tailored to their individual circumstances, he concludes.